Get started
Author

Cheng Xue

Observed name: XUE, CHENG
ORCID: 0009-0004-2322-9980
Observed ORCID: 0009-0004-2322-9980
OpenAlex ID: A5123550002
Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al. · Clinical Cancer Research · 2
Figure S13 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S28 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S12 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S32 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Data from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Table S5 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S24 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Table S7 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S5 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S15 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Table S4 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S18 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S29 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S9 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S8 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S4 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S7 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S26 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S3 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S23 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S1 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Table S2 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Figure S19 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Table S1 from Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody–Drug Conjugates
2026 · Anil P. Bidkar, Scott Bidlingmaier, et al.
Works count: 46
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type